Company ProfilePremium

Thomson Medical Group Limited

Company Profile Analysis

Ticker: A50.SI

ESOMAR 23 Corporate BadgeISO Certifications Badge
Thomson Medical Group Limited - Company showcase

Year Founded & Workforce

1979

Thomson Medical Group Limited logo

Thomson Medical Group Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Thomson Medical Group Limited Overview

Thomson Medical Group is a mid-sized, controller-owned Southeast Asian private hospital group operating in Singapore, Malaysia and Vietnam, with 816 licensed beds across three hospitals at 30 June 2026. Its franchise originates in Thomson Medical Centre, a 187-bed Singapore maternity and paediatric hospital that the company says delivers more than one in five Singapore births, supported by 36 clinics and centres. Around this core it has built a Bursa-listed Malaysian tertiary hospital platform (TMC Life Sciences, 70.1%-owned, anchored by 399-bed Thomson Hospital Kota Damansara and Malaysia's leading fertility chain) and, since December 2023, a JCI-accredited Vietnamese tertiary hospital (FV Hospital, Ho Chi Minh City). The investment case combines a defensive women's-and-children's brand being broadened into multi-specialty care with a large optionality asset: 26 acres of freehold waterfront land in Johor Bahru earmarked for the RM18 billion Johor Bay healthcare-led masterplan. The offsetting reality is high leverage (net debt/adjusted EBITDA of 12.1x) and three consecutive years of goodwill-driven losses or earnings compression.


What the company does

TMG is an investment holding company whose subsidiaries operate hospitals, specialist clinics and ancillary healthcare services. Its FY2026 results announcement describes the company's own principal activities as investments, investment holding and strategic investments, and those of its subsidiaries as operating hospitals and clinics and providing healthcare services. It reports four segments: Singapore, Malaysia and Vietnam (each comprising hospital and specialised services) and Investment Holdings (the Johor land bank held as investment and development property, and the group's central debt).

Company's own description (FY2026 press release, paraphrased)

The company presents itself as one of Southeast Asia's leading listed healthcare providers with operations in Singapore, Malaysia and Vietnam. In Singapore, Thomson Medical (founded 1979) offers women's health, fertility, paediatrics and specialist care, anchored by Thomson Medical Centre, close to 40 specialist clinics and facilities, and a 24/7 Urgent Care Centre. From its obstetrics, gynaecology, paediatrics and assisted-reproduction roots it now extends to oncology, orthopaedics, ENT, general surgery, health screening, diagnostic imaging, dentistry, specialist dermatology and Traditional Chinese Medicine. In Malaysia it operates through Bursa-listed TMC Life Sciences Berhad (Thomson Hospital Kota Damansara and TMC Fertility Centre) and owns the proposed Thomson Hospital Iskandariah in Johor Bahru. It also owns freehold waterfront land in Johor Bahru city centre for an integrated masterplan. In Vietnam, FV Hospital covers more than 30 specialties and operates the American Chiropractic Clinic network of three clinics.

Business and revenue model

Revenue line (FY2026)SGD Mn% of revenueNatureSource
Rendering of services, including sale of goods415.598.9Fee-for-service hospital and clinic billing (inpatient, day surgery, outpatient, diagnostics, pharmacy)FY2026 Note 5
Rental income4.61.1Leasing of medical suites/space to tenant specialists and othersFY2026 Note 5
Total420.1100.0——
Recognised at a point in time409.597.5Episodic careFY2026 Note 5
Recognised over time10.62.5Packages (e.g., maternity, health-screening, fertility programmes)FY2026 Note 5

The model is almost entirely service revenue; there is no meaningful product, subscription or licensing income. Two operating-model features are distinctive. First, in Singapore TMC runs a "tenant specialist" model in which independent obstetricians, paediatricians and other specialists practise from the hospital and its clinics while TMG captures facility, nursing, theatre, diagnostic and pharmacy revenue. Second, under Group CEO Dr Melvin Heng, TMG is using commercially incentivised partnerships with specialist groups (OncoCare in Malaysia and Singapore; NVTS Specialists in Singapore day surgery) rather than buying physician practices outright, an approach he described in a 2026 Edge Singapore interview as keeping doctors aligned rather than "cashed out".

Value-chain position, customers and end-markets

TMG sits at the provider layer: it owns and operates licensed hospital infrastructure, employs nursing and allied health staff, and contracts or hosts physicians. Upstream it buys drugs and consumables (S$110.2M in FY2026, rising with oncology volumes); downstream it is paid by self-pay patients, private insurers and third-party administrators, corporates, and (in Vietnam from 1 January 2026, per Vietnamese press) the national health-insurance scheme. Customer types include Singapore families (maternity, paediatrics, fertility), Malaysian domestic and medical-tourism patients (oncology, fertility, specialist surgery), and Ho Chi Minh City middle-class and expatriate patients plus regional patients from Cambodia, Laos and Myanmar.

Independent characterisation

TMG is best understood as three businesses of different quality joined by a levered holding company and a land bank. Singapore is a mature, high-margin (24.3% segment EBITDA margin in FY2026) maternity franchise whose volume base is shrinking with deliveries and whose growth now depends on pricing and specialty mix. Malaysia is the inflection story, with segment revenue up 19.0% and segment profit rising from S$0.9M to S$5.3M in FY2026 as oncology ramps. Vietnam is a quality asset bought at a full price (S$469.1M cash) whose goodwill has been written down twice (S$75.1M in FY2025, S$15.2M in FY2026). The holding layer carries S$998.2M of segment liabilities and absorbed S$43.9M of finance costs in FY2026, which is why the group reports losses despite all three operating segments being profitable at the segment level.

Strategy

Stated strategy themes (paraphrased from FY2026 briefing and results)

Management frames its strategy as a long-term plan set in motion in 2022 that is now showing through in operating performance, with the priority being to deepen the same model in each market and convert scale into earnings. The four stated focus areas for the year ahead are: building specialty depth; widening payor and cross-border access; improving utilisation and operating leverage; and maintaining disciplined capital allocation.

By country, the company's themes are: in Singapore, evolving from women's and children's health into a broader family-centred platform (general surgery, gastroenterology, ENT, orthopaedics), with broader payor access and pricing discipline lifting revenue intensity and theatre utilisation; in Malaysia, converting specialist expansion into earnings, led by oncology, with medical tourism as a key channel and Johor as the longer-term opportunity; in Vietnam, patient growth with capacity still to come through the H-wing expansion for oncology, diagnostics and advanced surgery.

Strategic initiatives in the last 24 months

InitiativeDateDescriptionStatusSource
Thomson OncoCare (Malaysia)Sep 2024 / Nov 2024Oncology partnership at THKD; drove Malaysia revenue +19% in FY2026OperatingBernama; FY2026
TMC rejuvenationFY2025Ground-floor rebuild, MRI suite, Urgent Care CentreCompletedAR2025; Edge 2026
Thomson OncoCare Cancer Centre at TMC2,025Oncology replicated in SingaporeOperatingEdge 2026
FV H BuildingAnnounced May 2025US$45M building, +6,700 sqm, oncology/IVF/GI/dialysisUnder constructionLe Petit Journal
FV grounds expansionLate 2025Permission for additional 10,000 sqm; planned centres of excellence in oncology, IVF, GI, cardiologyPlanningEdge 2026
Johor Bay25 Aug 2025RM18bn GDV healthcare-led masterplan on 26 acres; phase 1 hospital plus 47-storey residenceSeeking development partnersEdgeProp; Edge 2026
Payor broadeningFY2026Reduced corporate discounts; deeper insurer, TPA, broker and corporate relationships in Singapore; FV accepts national health insurance (Jan 2026)OngoingFY2026 announcement; Vietnamese press
Aspire Surgery CentreApr–Aug 202640% day-surgery JV with NVTS Specialists (S$1.12M)FormedFY2026 Note 17
Digital transformationFY2024–FY2026EMR rollout in Singapore; in-house software teams; higher digital spend cited as an opex driver in FY2026OngoingFY2026 announcement; Edge 2026
Clinical capability upgrades at THKDFY2026HIFU, HIPEC, CO2 laser, EUS, 3D imaging; MSQH 4-year accreditation, BFHI, ISO 15189CompletedFY2026 Briefing
Board refreshFeb 2026Property-experienced chairmanCompletedSGX
SustainabilityFY2024–FY2025TCFD-aligned climate reporting; net-zero 2050 commitmentOngoingAR2024/AR2025 summaries

Guidance and targets

TMG does not publish numeric financial targets. Its FY2026 announcement states that the group expects to continue incurring losses over the next 12 months as it continues investment, expansion and transformation. No cost-saving programme with quantified targets, no leverage target and no dividend resumption timetable have been disclosed. Management has linked Johor Bay to addressing gearing (FY2025 Press Release), but has not quantified expected proceeds or timing.

Products & Services

TMG sells healthcare services rather than products. Pricing is fee-for-service; package pricing is used for maternity, screening and fertility programmes (evidenced by the "over time" revenue line), but list prices are not disclosed in filings. The catalogue below is organised by segment.

Singapore (Thomson Medical Pte Ltd)

OfferingDescription and capabilitiesTarget customerLaunch / latestSource
Thomson Medical Centre (TMC)Flagship private hospital, 187 licensed beds (178 operational), O&G and paediatric focus; surgical operations, diagnostic imaging, pharmacy, laboratory; company states it accounts for more than 20% of Singapore births. FY2026 bed occupancy 49.4%Expectant mothers, familiesOpened 1979; ground-floor rebuild with new lobby, relocated pharmacy and blood bank completed under current CEO; official reopening in FY2025FY2026 Briefing; Edge interview 2026
24-hour Urgent Care CentreRound-the-clock care for non-life-threatening conditions staffed by doctors and nursesFamilies, walk-in patientsFY2025FY2026 Briefing; AR2025 summary
MRI SuiteFirst MRI within TMC, complementing X-ray and ultrasound at Thomson Diagnostic Imaging Centre (TDIC)Referred patientsFY2025FY2026 Briefing
Thomson Diagnostic Imaging CentreX-ray and ultrasound servicesInpatients, outpatientsExistingFY2026 Briefing
Thomson Women's ClinicsNetwork of O&G clinics across Singapore heartland and central locationsWomenExisting; network of 36 clinics and centres (vs 16 in 2010)FY2026 Briefing
Thomson Fertility Centre / egg freezingAssisted reproduction; elective egg freezing following July 2023 legalisation, with the company claiming one of the highest private-sector case countsCouples, women preserving fertilityEgg freezing from FY2024FY2024 Results Announcement
Thomson Paediatric Centre / paediatric clinicsOutpatient paediatric careChildrenExistingFY2026 Briefing
Thomson Specialists (Paragon)Multi-specialty centre at Paragon Medical Centre (rebranded from Thomson Wellth)Affluent patientsRebrand during FY2023AR2023
Thomson Breast Centre; Thomson Surgical CentreOne-stop breast centre at TMC; surgical centreWomen; surgical patients2,0192Q2019 press release
Thomson OncoCare Cancer Centre (at TMC)Oncology centre set up by OncoCare at TMCCancer patients2,025Edge interview 2026
Gynaecological oncology, health screening, dentistry, specialist dermatology, TCMAncillary specialist servicesFamiliesExistingFY2025 Press Release
New specialties: orthopaedics, ENT, general surgery, gastroenterologyComplementary family-focused surgery to lift theatre utilisationFamiliesFY2025–FY2026FY2026 Briefing
Aspire Surgery Centre (40% associate)Day-surgery operating theatre with NVTS SpecialistsSpecialist-referred patientsIncorporated Apr 2026; SHA Aug 2026FY2026 Note 17
LocationsNovena Medical Centre, Novena Specialist Centre, Orchard, Tiong Bahru, Katong, Serangoon, Tampines, Punggol, Sengkang, Sembawang, Woodleigh, Choa Chu Kang, Bukit Batok, Jurong East, United Square—At 30 Jun 2026FY2026 Briefing map

Malaysia (TMC Life Sciences Berhad)

OfferingDescription and capabilitiesTarget customerLaunch / latestSource
Thomson Hospital Kota Damansara (THKD)Tertiary multi-disciplinary hospital, 399 licensed beds (327 operational), expandable to 554; FY2026 occupancy 52.4%Klang Valley residents; medical touristsEst. 2008; expansion licensed 30 Mar 2022FY2026 Briefing
Thomson OncoCare / Oncology CentrePartnership with OncoCare Medical Malaysia offering precision oncology, immunotherapy, targeted therapy, tumour boards; drives most of Malaysia's FY2026 growthCancer patients incl. foreignAgreement 6 Sep 2024; operations Nov 2024Bernama; FY2026 Results
Urology/oncology technologyHIFU, laser TURP, targeted TRUS biopsyProstate cancer/BPH patientsFY2026FY2026 Briefing
Colorectal oncologyHIPEC (tumour removal with heated chemotherapy)Advanced abdominal cancerFY2026FY2026 Briefing
ENTCO2 laser systems; first in Malaysia to offer ENT, head and neck CO2 laser treatmentENT patientsFY2026FY2026 Briefing
Gastroenterology and hepatologyEUS and liver elastographyGI/liver patientsFY2026FY2026 Briefing
Orthopaedic and spine3D image intensifierSurgical patientsFY2026FY2026 Briefing
TMC Fertility CentreFour fertility centres (incl. Kota Damansara, Puchong, Ipoh, Johor Bahru); company describes it as Malaysia's industry leader in assisted reproductionCouplesNew entities for Ipoh, Penang, South incorporated FY2024FY2024 & FY2026 announcements
Thomson Specialist Clinics (Kepong) and other clinics3 other clinics and centresOutpatientsFY2024FY2024 announcement
LaboratoryFirst private hospital in Malaysia with total laboratory automation; MS ISO/IEC 15189 accreditedHospital-wideFY2026 accreditationFY2026 Briefing
Thomson Hospital Iskandariah (planned)Planned hospital approx. 1km from Johor CIQ; briefing shows 500 beds and 400 medical suites. CEO interview (2026) instead cites a hospital of about 300-plus beds at the masterplan's centre; discrepancy notedJohor and Singapore cross-border patientsUnder planning; FSMOne (Sep 2025) reports construction slated for early 2026 and operations by 2030FY2026 Briefing; Edge 2026; FSMOne

Vietnam (Far East Medical Vietnam Ltd)

OfferingDescription and capabilitiesTarget customerLaunch / latestSource
FV Hospital (District 7, HCMC)Multi-specialty private tertiary hospital with 30+ specialties; first JCI-accredited hospital in South Vietnam, four consecutive JCI accreditations; GFA 26,300 sqm; over 1,600 staff and over 200 doctors (briefing). Licensed beds 230, operational 186, occupancy 49.8%HCMC/Mekong Delta middle class, expatriates, CLM regionFounded 2003FY2026 Briefing
Centres of excellenceOncology, orthopaedics, cardiology, maternity, ophthalmology (incl. complex corneal transplants), gastroenterologyComplex-care patientsOngoingFY2026 Briefing; Edge 2026
Thoracic surgery centrePositioned as the region's first, serving Cambodia, Vietnam, Laos, MyanmarRegional patientsAnnounced Aug 2024FY2024 Results Announcement
H Building expansionUS$45M new building adding 6,700 sqm (above ground) for oncology, IVF, gastroenterology day-hospital endoscopy, dialysis; total campus to reach 37,500 sqm; further permission for 10,000 sqm of grounds in late 2025Specialist patientsAnnounced May 2025; in constructionLe Petit Journal; Edge 2026; Bao Phap Luat
American Chiropractic Clinic (ACC)Three chiropractic and sports-medicine clinics (District 5 and District 1 HCMC; Hanoi)Musculoskeletal patientsAcquired with FEMVNFY2026 Briefing
FV Saigon ClinicOutpatient clinic in central HCMCOutpatientsPre-acquisitionTMG release, 21 Dec 2023
National health-insurance acceptanceApplied across outpatient, inpatient and emergency services from 1 Jan 2026 (Vietnamese press; not confirmed in TMG filings)Insured mass-market patientsJan 2026Bao Phap Luat

Investment Holdings / Real estate

OfferingDescriptionStatusSource
Johor Bay masterplan26-acre (10.52ha) freehold waterfront site in JB city centre within the JS-SEZ, 1.2km from the Bukit Chagar RTS station; healthcare nucleus (hospital, specialist suites, aged-care living) plus luxury residences, five-star hotel, commercial-lifestyle precincts; phase 1 comprises Thomson Hospital Iskandariah and a 47-storey residential towerLaunched 25 Aug 2025; GDV RM18bn (approx. US$4.3bn). The 2026 CEO interview cites a projected GDV of S$5.5bn; management in advanced talks with development partnersEdgeProp; Forbes; Edge 2026

Financial Narrative

All figures S$M, fiscal years ended 30 June, audited, from TMG FY2023, FY2024 and FY2026 Results Announcements (each year's figures taken from that year's or the following year's audited statements). FY2024 balance-sheet equity was later restated from 578.2 to 577.0 upon finalisation of the FEMVN purchase price allocation (FY2025 statement of changes in equity opens at 577.0).

Income statement

Adjusted EBITDA definitions: FY2023–FY2024 exclude one-off transactions and non-recurring costs (FEMVN deal costs and FX loss); FY2025 excludes S$75.1M goodwill impairment and S$54.6M reversal of impairment on development and investment properties; FY2026 excludes S$15.2M goodwill impairment.

Margins and growth (computed)

Revenue CAGR FY2022–FY2026 (computed): 5.9%. Company-defined "core revenue" (excluding COVID projects) grew 73% from S$228.5M in FY2021 to S$394.7M in FY2025 (FY2025 Press Release).

Commentary. The five-year record divides into two regimes. FY2022–FY2023 margins were inflated by COVID-era government project income (vaccination centres, Transitional Care Facilities) and Job Support Scheme grants; adjusted EBITDA margins above 30% were not structural. FY2024 was the hinge: COVID income ended in December 2023 while FEMVN was consolidated for six months, and acquisition borrowing lifted finance costs by 69% to S$51.6M. FY2025 was the trough: FEMVN's full-year consolidation dragged margins down (Vietnam's EBITDA margin is roughly 10 points below Singapore's), Malaysia suffered from terminated insurer contracts and pricing adjustments, and a S$75.1M goodwill impairment produced the first loss since FY2020. FY2026 shows tentative recovery: adjusted EBITDA grew 9.9%, faster than revenue, finance costs fell S$10.5M as SORA-linked loan rates eased, and the loss narrowed 40.8%. The falling gross-margin proxy (83.4% to 73.8%) reflects mix shift toward drug-intensive oncology and lower-priced Vietnamese care rather than pricing weakness; Singapore inpatient average bill size rose 21.8% in FY2026 alone.

Balance sheet

Goodwill by CGU at 30 Jun 2026: TMPL S$379.8M; TMCLS S$42.9M; BBWF S$61.4M; FEMVN S$275.3M (down from S$406.4M provisional in FY2024). The FY2024 goodwill figure of S$880.5M includes provisional FEMVN goodwill before purchase price allocation reclassified part to identifiable intangibles (brand name rose from S$3.9M to S$25.8M).

Commentary. The FEMVN purchase (S$469.1M cash; S$460.0M net of cash acquired) was funded overwhelmingly by debt and cash: gross borrowings rose S$358M in FY2024 and cash fell S$119M, taking net debt from S$461M to S$939M. Equity has since eroded by S$52.7M through losses and goodwill write-downs while net debt continued to drift up to S$990.7M, so the balance sheet has de-levered by nothing since the deal. Goodwill and intangibles equal 151% of total equity at 30 Jun 2026, meaning tangible equity is negative on a consolidated basis. The Johor land is carried at cost less impairment (investment property S$144.0M; development property S$135.5M; BBWF PPE S$89.8M); management states it is "well undervalued" on the books (Edge interview, 2026), and the investment property's disclosed fair-value input is MYR900 per sq ft.

Cash flow

Commentary. Free cash flow before interest has remained positive throughout, but it no longer covers interest and lease payments. In FY2026 FCF of S$51.0M compared with S$58.5M of interest plus lease principal, producing the S$11.4M net cash outflow. Capex was cut sharply in FY2026 (S$15.3M versus S$22.6M), which supports near-term cash but sits awkwardly with funding the FV H Building (US$45M) and any Johor equity contribution. Operating cash flow recovered 17.4% in FY2026, aided by tax paid falling from S$7.6M to S$2.0M.

Ratios (computed unless stated)

ROIC uses a 17% notional tax rate and invested capital defined as gross borrowings plus total equity less cash. The FY2022 ROE denominator uses opening equity at 1 July 2021 of S$489.8M. A full cash conversion cycle is not computable because TMG does not separately disclose trade payables days for the group; receivable days are shown as the closest available proxy. Company-reported net-debt-to-adjusted-EBITDA is 11.2x (Jun 2024), 13.1x (Jun 2025) and 12.1x (Jun 2026) per the FY2026 Results Briefing; the analyst's FY2026 figure of 12.0x differs only because the company includes S$3.3M of finance lease in debt.

Commentary on ratios. Every leverage and coverage metric deteriorated step-wise with the Vietnam deal and has improved only marginally since. The critical number is adjusted EBITDA cover of finance costs at 1.68x; EBIT does not cover interest (0.53x). Absent asset monetisation at Johor Bay, de-levering depends on EBITDA growth: holding net debt flat, adjusted EBITDA would need to reach roughly S$165M (double FY2026) to bring net debt/EBITDA to 6x.

Half-year progression

1H FY2026 adjusted EBITDA is derived (FY2026 S$82.5M less 2H S$43.6M). The 2H losses in both years include the annual goodwill impairment test charge.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityJurisdictionRoleOwnershipSource

Thomson Medical Group Limited

Singapore

Listed holding company; issuer of MTNs

—

Filings

Sasteria Pte Ltd

Singapore

Intermediate holding company (penultimate holder of TMCLS)

100%

TMCLS FY2026 directors' report

Thomson Medical Pte Ltd (TMPL)

Singapore

Owns and operates Thomson Medical Centre and Singapore clinics

100%

FY2026 Note 17

Sasteria (M) Pte Ltd

Singapore

Immediate holding company of TMCLS

100%

TMCLS FY2026 directors' report

TMC Life Sciences Berhad (TMCLS)

Malaysia (Bursa)

Operates THKD and TMC Fertility

approx. 70.1% (1,221,638,155 shares)

Simply Wall St shareholder register

BB Waterfront Sdn Bhd (BBWF)

Malaysia

Wholly owned subsidiary of TMCLS that owns the Thomson Iskandar / Thomson Hospital Iskandariah site

100% of TMCLS

FY2026 Note 11

Sasteria (VN) Pte Ltd; FVH Singapore Pte Ltd

Singapore

Holding vehicles for Vietnam (incorporated June 2023)

100%

FY2023 Results Announcement

Far East Medical Vietnam Ltd (FEMVN)

Vietnam

Operates FV Hospital and ACC clinics

100%

FY2024 Note 13

Aspire Surgery Centre Pte Ltd

Singapore

Day-surgery operating theatre (with NVTS Specialists)

40% associate (incorporated 24 Apr 2026)

FY2026 announcement

Thomson X Pte Ltd

Singapore

Health-tech venture vehicle

100% (per director listings)

GlobalData; 2021 press

Segment Overview

SegmentContentsKey assets

Singapore

Hospital and specialised services in Singapore

Thomson Medical Centre (187 licensed beds), 36 clinics and centres, Thomson Diagnostic Imaging Centre, MRI Suite, 24-hour Urgent Care Centre, fertility, paediatric, women's, TCM, dental, dermatology clinics

Malaysia

Hospital and specialised services in Malaysia via TMCLS

THKD (399 licensed beds, 554 maximum capacity), Oncology Centre, 4 TMC fertility centres, 3 other clinics

Vietnam

Hospital and specialised services in Vietnam via FEMVN

FV Hospital, District 7, HCMC (230 licensed beds); 3 American Chiropractic Clinics (District 5, District 1 HCMC; Hanoi)

Investment Holdings

Johor investment property and development property, holding-company financing

Freehold land in Iskandar Development Region (investment property S$144.0M, development property S$135.5M, BBWF land in PPE S$89.8M at 30 Jun 2026)

Revenue by Segment

Segment (SGD Mn, FY ends 30 Jun)FY2023FY2024FY2025FY2026

Singapore revenue

260.4200.2190.4192.9

Malaysia revenue

95.0100.1105.3125.3

Vietnam revenue

050.498.4101.3

Investment Holdings revenue

0.40.40.50.5

Group revenue

355.8351.2394.7420.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment Margins & Growth (%) and Revenue by Segment (%)

Metric (%)FY2024FY2025FY2026

Singapore revenue YoY growth

-23.1-4.91.3

Malaysia revenue YoY growth

5.55.219.0

Vietnam revenue YoY growth

—95.32.9

Singapore share of group revenue

57.048.245.9

Malaysia share of group revenue

28.526.729.8

Vietnam share of group revenue

14.424.924.1

Results by Segment

Segment metric (SGD Mn)FY2023FY2024FY2025FY2026

Singapore segment profit after finance costs

60.228.624.922.6

Malaysia segment profit

11.711.50.95.3

Vietnam segment profit

04.12.73.0

Investment Holdings segment loss

-30.8-24.7-75.5-58.6

Group profit/(loss) for the year

41.119.5-47.0-27.8

Segment EBITDA (SGD Mn, company-reported)

Segment EBITDA (SGD Mn, company-reported)FY2025FY2026

Singapore EBITDA

48.546.8

Malaysia EBITDA

14.021.4

Vietnam EBITDA

15.014.8

Investment Holdings EBITDA (reported, incl. impairments/reversals)

-22.9-15.7

Investment Holdings adjusted EBITDA

-2.4-0.5

Group EBITDA

54.667.3

Group adjusted EBITDA

75.182.5

Segment margin (%)

Segment margin (%)FY2024FY2025FY2026

Singapore EBITDA margin (company)

—25.524.3

Malaysia EBITDA margin (company)

—13.317.0

Vietnam EBITDA margin (company)

—15.314.6

Singapore segment-profit margin (computed)

14.313.111.7

Malaysia segment-profit margin (computed)

11.50.94.3

Vietnam segment-profit margin (computed)

8.12.72.9

Revenue by Segment (FY2022–FY2023)

Old segment (SGD Mn)FY2022FY2023

Hospital Services revenue

162.5186.3

Specialised Services revenue

170.9169.1

Investment Holdings revenue

0.30.4

Hospital Services profit before tax

37.139.1

Specialised Services profit before tax

56.846.5

Investment Holdings loss before tax

-24.7-30.3

Segment Overview — Singapore

SegmentAssetsLiabilitiesAdditions to non-current assets

Singapore

673.4147.124.1

Malaysia

411.280.27.0

Vietnam

365.523.310.6

Investment Holdings

324.1998.20.03

Group

1,774.21,248.741.7

Income Statement and Per-Share Data

Metric (SGD Mn)FY2022FY2023FY2024FY2025FY2026

Revenue

333.7355.8351.2394.7420.1

Other income

9.85.631.560.96.5

Inventories and consumables used

55.359.475.299.3110.2

Gross profit proxy (revenue less consumables; not reported by TMG)

278.4296.4275.9295.3309.9

Staff costs

107.9118.0121.8135.5140.9

Depreciation and amortisation

17.921.127.538.741.0

Other operating expenses (incl. impairments)

70.580.783.2166.1108.2

Results from operating activities (EBIT)

91.882.375.015.926.3

EBITDA (company-reported)

109.7103.3102.454.667.3

Adjusted EBITDA (company)

109.7106.6109.875.182.5

Finance income

1.03.97.43.61.8

Finance costs

23.530.551.659.749.2

Net finance costs

22.526.644.256.047.4

Profit/(loss) before tax

69.355.230.6-40.6-21.1

Income tax expense

10.714.111.16.46.7

Profit/(loss) for the year

58.641.119.5-47.0-27.8

Attributable to owners (PATMI)

53.836.615.4-47.6-29.7

Attributable to non-controlling interests

4.84.54.10.61.9

EPS basic (S$ cents)

0.2030.1380.058-0.180-0.112

EPS diluted (S$ cents)

0.2030.1380.058-0.180-0.112

Dividend per share declared for the year (S$ cents)

0.1150.040000

Margin / growth (%)

Margin / growth (%)FY2022FY2023FY2024FY2025FY2026

Revenue growth YoY

—6.6-1.312.46.4

Gross margin proxy

83.483.378.674.873.8

Operating (EBIT) margin

27.523.121.34.06.3

EBITDA margin (reported)

32.929.029.213.816.0

Adjusted EBITDA margin

32.930.031.319.019.6

Pre-tax margin

20.815.58.7-10.3-5.0

Net margin

17.611.55.6-11.9-6.6

Balance Sheet and Per-Share Data

Metric at 30 Jun (SGD Mn)FY2022FY2023FY2024FY2025FY2026

Total assets

1,364.91,447.81,807.41,784.61,774.2

Cash and short-term deposits

161.6286.6167.3124.2113.1

Short-term borrowings

227.712.1189.2163.9201.8

Long-term borrowings

401.4735.6917.0942.0902.0

Total borrowings (excl. leases)

629.1747.81,106.21,105.91,103.8

Lease liabilities

13.815.015.215.726.2

Net debt (excl. leases, computed)

467.5461.2938.9981.7990.7

Net debt (company, incl. finance lease)

——938.9981.7994.0

Total equity

608.3575.4578.2548.4525.5

Equity attributable to owners

531.7499.4500.9470.9442.4

Non-controlling interests

76.776.077.377.583.1

Goodwill

483.4474.8880.5788.1759.3

Total intangible assets (incl. goodwill)

484.1481.6895.5825.0791.5

Current assets

320.5440.9316.8319.5323.7

Current liabilities

338.5120.0292.1268.8311.0

Working capital (computed)

-18.0320.824.750.812.7

NAV per share (S$ cents)

2.302.182.192.071.99

Cash Flow

Metric (SGD Mn)FY2022FY2023FY2024FY2025FY2026

Operating cash flow before working capital

110.1105.777.775.782.0

Net cash from operating activities

92.888.683.460.471.0

Purchase of property and equipment (capex)

27.811.226.922.615.3

Purchase of intangible assets

0.41.63.54.14.7

Free cash flow (OCF less capex and intangibles, computed)

64.775.853.033.851.0

Acquisition of subsidiary, net of cash

00460.000

Interest paid

22.131.149.761.048.8

Lease principal paid

6.46.67.58.89.7

Dividends paid to owners

4.030.410.600

Dividends paid to NCI

1.11.52.33.90.5

Share buybacks

00000

Net borrowings drawn/(repaid)

10.2123.5358.0-4.3-5.9

Net change in cash and equivalents

39.9129.4-125.3-37.9-11.4

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE (PATMI / avg owners' equity, %)

10.57.13.1-9.8-6.5

ROA (profit / avg total assets, %)

4.32.91.2-2.6-1.6

ROIC (EBIT × 0.83 / avg invested capital, %)

7.16.54.90.91.4

Current ratio (x)

0.953.671.081.191.04

Gross debt / equity (x)

1.031.301.912.022.10

Net debt / equity (x)

0.770.801.621.791.89

Net debt / reported EBITDA (x)

4.34.59.218.014.7

Net debt / adjusted EBITDA (x, company basis)

——11.213.112.1

EBITDA / finance costs (x)

4.673.391.990.921.37

Adjusted EBITDA / finance costs (x)

4.673.492.131.261.68

EBIT / finance costs (x)

3.912.701.450.270.53

Asset turnover (revenue / avg assets, x)

0.240.250.220.220.24

Receivable days (year-end receivables / revenue × 365)

6664455255

Income Statement

Metric (SGD Mn)1H FY20252H FY20251H FY20262H FY2026

Revenue

199.1195.6213.1207.0

Profit/(loss) after tax

-12.6-34.4-9.1-18.7

EBITDA (reported)

—15.5—28.4

Adjusted EBITDA

—36.038.943.6

Revenue by Region

Region (SGD Mn)FY2022FY2023FY2024FY2025FY2026

Singapore

254.6260.4200.2190.4192.9

Malaysia

79.195.4100.5105.8125.9

Vietnam

0050.498.4101.3

Total

333.7355.8351.2394.7420.1

Geographic growth (%)

Geographic growth (%)FY2023FY2024FY2025FY2026

Singapore YoY

2.3-23.1-4.91.3

Malaysia YoY

20.55.45.319.0

Vietnam YoY

——95.32.9

Revenue by Region (%)

Geographic mix (% of revenue)FY2022FY2023FY2024FY2025FY2026

Singapore

76.373.257.048.245.9

Malaysia

23.726.828.626.830.0

Vietnam

0014.424.924.1

Revenue by Region — Singapore

Region (SGD Mn)FY2022FY2023FY2024FY2025FY2026

Singapore

594.6596.0603.5609.7612.2

Malaysia

449.8410.9421.6471.7491.9

Vietnam

00465.4383.6346.4

Revenue by Region (%) and Revenue by Region (SGD)

StatisticFY2024FY2025FY2026

Licensed beds, Singapore

187187187

Licensed beds, Malaysia

373403399

Licensed beds, Vietnam

230230230

Operational beds, Singapore

178178178

Operational beds, Malaysia

341310327

Operational beds, Vietnam

198188186

Bed occupancy, Singapore (%)

56.354.749.4

Bed occupancy, Malaysia (%)

55.649.052.4

Bed occupancy, Vietnam (%)

50.046.349.8

Inpatients, Singapore

14,73814,65813,319

Inpatients, Malaysia

24,51221,07218,659

Inpatients, Vietnam

7,3236,6117,042

Outpatients, Singapore

254,934244,246237,893

Outpatients, Malaysia

188,567201,596210,094

Outpatients, Vietnam

237,789230,726246,550

Inpatient avg bill, Singapore (SGD)

5,5036,3187,696

Inpatient avg bill, Malaysia (ZAR Mn)

9,99210,77912,065

Inpatient avg bill, Vietnam (USD)

4,1034,2504,340

Outpatient avg bill, Singapore (SGD)

331355387

Outpatient avg bill, Malaysia (ZAR Mn)

428551752

Outpatient avg bill, Vietnam (USD)

188185186

Share Price History

DatePrice (SGD)ContextSource

8 Jun 2023

0.059

FV talks confirmed

The Edge

28 Aug 2023

0.058

FY2023 results; down 27.5% YTD

The Edge

19 Sep 2023

0.059

Float breach

The Edge

4 Apr 2024

0.054

Float restored

The Edge

26 Aug 2024

0.050

FY2024 results

The Edge

12 Feb 2025

0.044

1H FY2025 loss

The Edge

25 Aug 2025

0.049

Johor Bay launch; down 2% YTD

The Edge

11 Feb 2026

0.062

1H FY2026; up about 55% over 12 months

The Edge

6 Oct 2026

0.049

Latest available quote

MarketInOut

Valuation Multiples

MultipleTMGBasis

Market capitalisation

S$1.30bn

26.44bn shares

Enterprise value

approx. S$2.37bn

Market cap + net borrowings S$990.7M + NCI S$83.1M (excl. leases)

P/E

Not meaningful (loss)

FY2026 EPS -0.112 cents

EV/EBITDA (reported FY2026)

35.2x

EBITDA S$67.3M

EV/EBITDA (adjusted FY2026)

28.7x

Adjusted EBITDA S$82.5M

EV/Sales

5.6x

Revenue S$420.1M

P/B

2.46x

NAV/share 1.99 cents

Analyst Ratings & Targets

BrokerDateRatingTarget (SGD)NoteSource

Phillip Securities (Paul Chew)

11 Sep 2026

BUY (upgraded on share price weakness)

0.071

FY26 revenue and EBITDA at 97%/98% of forecast; FY27e unchanged

POEMS

Phillip Securities

25 Feb 2026

Not stated in source

—

Cut FY26 EBITDA estimate 17% to S$84M

POEMS

Maybank Securities (Eric Ong)

Aug 2024

BUY

0.06 (from 0.08)

Called FY2025 a transitional year

The Edge

DBS (unrated note)

c. 2024

Unrated

—

Described TMG as a "diamond in the rough"

The Edge tag listing

Dividend (S$ cents per share, by fiscal year declared)

Dividend (S$ cents per share, by fiscal year declared)FY2022FY2023FY2024FY2025FY2026

Dividend per share

0.1150.040000

Cash dividends paid to owners in year (SGD Mn)

4.030.410.600

Capital Instruments

InstrumentCouponMaturityPrincipal (SGD Mn)

Series 004 notes (S$155M + S$20M tap)

5.25%

May 2027

175

Series 003 notes (S$120M + S$30M + S$25M)

5.50%

May 2028

175

Series 005 notes (S$160M + S$25M tap)

4.65%

Oct 2029

185

Secured bank loans – current

Floating (largely)

Within 12 months

26.8

Secured bank loans – non-current

Floating (largely)

Beyond 12 months

542.5

Lease liabilities

—

Various

26.2

Maturity bucket (SGD Mn, carrying)

FY2027

FY2028

FY2029

Medium-term notes maturing

1751750

Analyst Conclusions

Management guidance

TMG guides only qualitatively: it expects continued losses over the next 12 months while investment, expansion and transformation continue; it sees growth opportunities in private healthcare and medical tourism; and it will deepen insurer, TPA, corporate and broker relationships in Singapore, build on THKD's oncology and reproductive medicine platform in Malaysia while progressing Iskandariah, and expand FV's tertiary capability through the H Building (FY2026 Results Announcement, para 4).

Consensus

No formal consensus is published. Phillip Securities maintains FY2027 forecasts unchanged after FY2026 results and a S$0.071 target; its February 2026 FY2026 EBITDA estimate of S$84M versus actual adjusted EBITDA of S$82.5M indicates the broker's figures are tracking adjusted EBITDA. Simply Wall St's 2024 snapshot showed analysts forecasting about 6.9% annual revenue growth over three years, consistent with the FY2022–FY2026 CAGR of 5.9%.

Bull case

  1. Operating leverage is appearing. Adjusted EBITDA grew 9.9% on 6.4% revenue growth in FY2026, Malaysia segment EBITDA rose 52% to S$21.4M, and THKD still has 227 beds of licensed-to-maximum headroom. If Malaysia continues at FY2026's trajectory and Vietnam's H Building adds oncology and IVF capacity, adjusted EBITDA above S$100M within two to three years is plausible.

  2. Johor Bay is a de-levering lever. A partner-funded development on 26 freehold acres with RM18bn GDV could crystallise value well above the roughly S$369M combined book value of the land, directly addressing net debt of S$994M, as management has explicitly linked the project to gearing.

  3. Interest costs are falling. Net finance costs fell S$8.6M in FY2026; refinancing the S$175M 5.25% 2027 notes and repricing floating bank debt at lower rates would add several million dollars of pre-tax profit a year, helping close the gap from a S$21.1M pre-tax loss.

Bear case

  1. The balance sheet leaves no margin for error. EBIT covers finance costs only 0.53x, free cash flow after interest and leases is negative, and S$201.8M of borrowings are current. Any payor shock similar to Malaysia's FY2025 contract losses or a rate rise would push leverage higher.

  2. Vietnam may keep disappointing. The earn-out was missed, two impairments totalling S$90.3M have been taken, Vietnam's EBITDA margin is slipping (15.3% to 14.6%), national insurance adoption dilutes pricing, and the 14.4% discount rate still leaves S$275.3M of goodwill exposed.

  3. Volume decline undermines the core. Group inpatients have fallen 16% in two years and Singapore occupancy is below 50%; price-led growth through average bill size cannot compound indefinitely against declining births and payor resistance.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timingWhat to watch
FY2026 Annual Report and AGMOct 2026 (expected)Director remuneration, risk section, sustainability data
Johor Bay development partner announcementUndatedStructure (land sale, JV, lease), cash proceeds, use against debt
Refinancing of S$175M May 2027 notesBefore May 2027Coupon versus 5.25%; any new MTN tranche
1H FY2027 resultsFeb 2027 (expected)Malaysia momentum, Singapore volumes under new CEO, Vietnam FX
FV H Building opening—Capacity, oncology/IVF launch
Permanent Singapore CEO appointmentUndisclosedLeadership stability
Thomson Hospital Iskandariah construction startFSMOne cited early 2026; status not confirmedCapex funding source
Goodwill testing at 30 Jun 2027Aug 2027FEMVN discount-rate assumptions

Analyst verdict

Thomson Medical Group is a good collection of healthcare assets trapped inside a stretched capital structure. Each operating segment is profitable, revenue intensity is rising in all three markets, and the Malaysian oncology build-out shows that management's partnership model can create earnings quickly and with little capital. The FY2026 results mark the first year since the FV acquisition in which adjusted EBITDA grew faster than revenue, operating cash flow rose, and losses narrowed materially. On an operating view, the turnaround narrative is credible.

The equity case, however, rests on what happens at the holding company. Net debt of almost S$1bn against S$82.5M of adjusted EBITDA means that nearly all of the operating improvement is still being consumed by interest, and shareholders have absorbed S$90.3M of goodwill write-downs on the Vietnam deal in two years. With EBIT covering interest roughly half a time, organic de-levering is slow; at the current pace, reaching a conventional 5–6x leverage ratio would take most of a decade. The decisive variable is therefore Johor Bay. If management lands a credible development partner and converts part of the land's latent value into cash, the market's premium multiple (about 29x adjusted EBITDA, roughly double IHH) becomes defensible. If the partnership drags, the valuation looks stretched for a loss-making, controller-dominated company with a 10% free float and no dividend.

For institutional investors, the equity is a special situation rather than a core healthcare holding: liquidity is thin, governance is concentrated, and outcomes are binary around the Johor transaction. The senior unsecured notes, by contrast, benefit from positive operating cash flow, spread maturities (2027, 2028, 2029) and asset backing from the land and hospitals, and appear to offer the better risk-adjusted exposure to the turnaround. Overall assessment: operationally improving, financially fragile, with valuation contingent on asset monetisation that has been announced but not yet delivered.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleIndependenceTenure / appointmentBackgroundAgeSource

Tan Sri Tong Kooi Ong

Chairman

Independent, Non-Executive

Since 1 Feb 2026

Founder and chairman, The Edge Media Group; Executive Chairman, Avarga Ltd (SGX); appointed for property and capital-intensive development experience

66 (GlobalData)

SGX 12 Jan 2026

Lim Wee Kiat (Kiat Lim)

Executive Vice-Chairman

Executive; son of controlling shareholder Lim Eng Hock

Director since Mar 2019; ED from Jan 2022; EVC from 1 Sep 2022 (FY2024 filing shows position from 1 Jan 2022; discrepancy noted)

Responsible for group growth strategy and M&A; former CEO of Thomson X; director of RSP Architects

33 (FY2026 filing)

FY2023/FY2026 announcements

Dr Heng Jun Li Melvin

Executive Director and Group CEO

Executive

Joined 2022; Group CEO by Aug 2023

Former CEO and COO, Gleneagles Hospital (GlobalData); acting Group CEO of TMCLS 29 Jan 2024 to 10 Feb 2025

42 (GlobalData, dated)

GlobalData; Simply Wall St

Wilson Sam

Executive Director and Group CFO

Executive

Since 15 Mar 2019

Former SVP Investments, Kestrel Capital; B.Bus (Hons), Nanyang Technological University

49 (GlobalData)

SGX 14 Mar 2019

Ong Pang Liang

Non-Executive Director

Non-independent (previously independent, on board since at least May 2019)

Approx. 7+ years

Not detailed in sources reviewed

—

SGX announcements

Christina Teo Tze Wei

Non-Executive Director; Chair, NRC

Independent

Since 1 Jan 2022

Not detailed in sources reviewed

—

SGX 1 Jan 2022

June Leong Lai Ling

Non-Executive Director; Chair, ARC

Independent

Since 1 Jan 2022

Not detailed in sources reviewed

—

SGX 1 Jan 2022

“—” = not publicly disclosed.

Executive Leadership Team

NameTitleSinceBackgroundSource

Cassandra Loh Wei Ning

Acting CEO, Thomson Medical Singapore, and Chief Commercial Officer

Acting CEO from 1 Jul 2026

Senior roles at Intellect, Cigna Singapore (Lead, Health and Wellness), Parkway Pantai/IHH; MSc Communications Management, SMU

SGX 1 Jun 2026

Dr Jean-Marcel Guillon

Founder and CEO, FV Hospital

Founder (2003)

French physician; led FV through acquisition

TMG release Dec 2023; Le Petit Journal 2025

Dr Siva Kumaran Jayaraman

Acting CEO, Thomson Hospital Kota Damansara (as of Sep 2024)

2024

Not detailed

Bernama, Sep 2024

Seah Sin Yuen

Company Secretary

——

SGX filings 2026

Board & Management Changes

DateChangeContextSource

29 Jan 2024

TMCLS Group CEO Wan Nadiah suspended; Dr Heng acting Group CEO of TMCLS

No reasons disclosed; outcome not publicly disclosed in sources reviewed

Bernama; The Edge

10 Feb 2025

Dr Heng ceases acting Group CEO role at TMCLS (remains non-executive director there)

—

Simply Wall St

12 Jan 2026

Tong Kooi Ong named Chairman from 1 Feb 2026, succeeding Ng Ser Miang (chairman since 2015)

Positioned for Johor Bay development phase

SGX

1 Jun 2026

Cassandra Loh named Acting CEO, Singapore, from 1 Jul 2026, succeeding Lee Suen Ming

Integrate commercial strategy with operations

SGX; Edge

Major Shareholders

HolderStakeDateSource

Lim Eng Hock (Peter Lim), direct and deemed

approx. 89.6%

Sep 2023

The Edge Singapore

Public float

10.15% (2,685,007,380 shares, >8,000 holders)

4 Apr 2024

SGX announcement

Ng Ser Miang (former chairman)

0.059%2025

Simply Wall St

Another independent director (not named in source)

0.057%2025

Simply Wall St

Competitive Landscape

Competitors by Segment

Market / segmentCompetitorTypePositioning vs TMG

Singapore private hospitals

IHH Healthcare (Parkway Pantai: Mount Elizabeth, Mount Elizabeth Novena, Gleneagles, Parkway East)

Listed (Bursa/SGX)

Dominant premium tertiary operator; competes in O&G and paediatrics at Gleneagles/Mount Elizabeth

Singapore

Raffles Medical Group (Raffles Hospital, clinics, insurance)

Listed (SGX)

Integrated provider-insurer; net-cash balance sheet

Singapore maternity

KK Women's and Children's Hospital

Public (SingHealth)

Largest births volume; subsidised pricing

Singapore private

Mount Alvernia Hospital; Farrer Park Hospital

Private / not-for-profit

Maternity and general private competitors

Singapore specialist O&G

Singapore O&G Ltd and private specialist groups

Listed / private

Doctor-owned specialist clinics that refer to multiple hospitals

Malaysia private hospitals

KPJ Healthcare

Listed (Bursa)

Largest Malaysian private network (30th hospital opened Mar 2025)

Malaysia

IHH (Pantai, Gleneagles, Prince Court, Island Hospital)

Listed

Premium tertiary; strong medical tourism

Malaysia

Sunway Healthcare

Private/listed group

Klang Valley tertiary competitor near Kota Damansara

Johor

KPJ Johor hospitals; Gleneagles Medini; Regency Specialist Hospital; Columbia Asia Iskandar

Various

Incumbents for the planned Iskandariah hospital (CEO says nearest are 20–25 minutes away)

Vietnam (HCMC)

Vinmec (Vingroup); Hoan My Medical Group; Tam Anh General Hospital; City International Hospital; Raffles Medical (Vietnam stake)

Private

Vinmec and Tam Anh scale fast; FV differentiated by JCI and French heritage

Fertility (Malaysia/Singapore)

Independent IVF chains

Private

TMC Fertility claims Malaysian leadership

Peer Comparison FY2026

MetricTMG (FY Jun 2026)IHH Healthcare (FY Dec 2025)Raffles Medical Group (FY Dec 2025)KPJ Healthcare (FY Dec 2025)

Revenue

S$420.1M

RM25.7bn reported (core RM26.2bn)

S$765.3M

RM4.26bn

Revenue growth

6.4%

6% reported (18% core)

1.8%9.2%

EBITDA

S$67.3M reported; S$82.5M adjusted

RM5.6bn

S$135.0M

—

EBITDA margin

16.0% reported; 19.6% adjusted

approx. 21.8%

approx. 17.6%

—

Net profit

-S$27.8M

PATMI ex-exceptionals RM2.3bn

PAT S$71.1M

PAT RM402M; net profit RM365.9M

Net margin

-6.6%

approx. 8.8% (on core revenue)

9.3%

approx. 9.4% (PAT)

Balance sheet

Net debt S$994M; 12.1x adjusted EBITDA

—

Net cash S$261M

—

“—” = not publicly disclosed.

Company Snapshot

$320.7M

Revenue

1979

Founded

Singapore

Headquarters

SWOT Analysis

Strengths

  • Dominant private maternity franchise: TMC handles more than 20% of Singapore births annually (company, The Edge Singapore 2026), anchoring a Singapore segment with a 24.3% EBITDA margin in FY2026.
  • Pricing power in Singapore: inpatient average bill rose from S$5,503 (FY2024) to S$7,696 (FY2026), +40% in two years (FY2026 Briefing).
  • Malaysian oncology turnaround: Malaysia segment profit rose from S$0.9M (FY2025) to S$5.3M (FY2026); TMCLS PATMI rose from RM3.6M to RM17.4M (TMCLS audited accounts).
  • Quality accreditation in Vietnam: FV is the first JCI-accredited hospital in South Vietnam, with four consecutive accreditations (FY2026 Briefing).
  • Positive operating cash flow: S$71.0M in FY2026, up 17.4%; FCF before interest of S$51.0M (FY2026 Results; computed).
  • Strategic land bank: 26 freehold acres in JB city centre within the JS-SEZ, 1.2km from RTS, carried at cost (investment property S$144.0M plus development property S$135.5M plus BBWF land S$89.8M) with management describing it as undervalued (FY2026 Notes 10/12/14; Edge 2026).
  • Capital-light specialist expansion: OncoCare and NVTS partnerships add capability for minimal capital (S$1.12M for 40% of ASC).

Weaknesses

  • High leverage: net debt S$994.0M; net debt/adjusted EBITDA 12.1x; net debt/equity 1.9x (FY2026 Briefing).
  • Weak interest cover: adjusted EBITDA/finance costs of 1.68x and EBIT/finance costs of 0.53x in FY2026 (computed).
  • Recurring losses: net losses of S$47.0M (FY2025) and S$27.8M (FY2026), with further losses guided for the next 12 months (FY2026 Results).
  • Low utilisation: bed occupancy of 49.4% (Singapore), 52.4% (Malaysia), 49.8% (Vietnam) in FY2026 (FY2026 Briefing).
  • Volume decline: group inpatients fell from 46,573 (FY2024) to 39,020 (FY2026), -16% (FY2026 Briefing).
  • Negative tangible equity: goodwill and intangibles of S$791.5M exceed total equity of S$525.5M (FY2026 balance sheet).
  • Thin float and controller concentration: float briefly breached SGX's 10% minimum (Sep 2023–Apr 2024).

Opportunities

  • Johor Bay monetisation: RM18bn GDV masterplan with development partners could crystallise land value and reduce gearing (FY2025 Press Release).
  • FV capacity expansion: US$45M H Building and an extra 10,000 sqm of grounds for oncology, IVF, GI and cardiology centres (Le Petit Journal; Edge 2026).
  • THKD headroom: 399 licensed beds versus 554 maximum capacity and 327 operational, allowing growth without major capex (FY2026 Briefing).
  • Falling rates: net finance costs fell 15.4% in FY2026 on lower interest rates; refinancing of the S$175M 5.25% 2027 notes at lower coupons would add further relief (FY2026 Results).
  • Replicating OncoCare/Tamarind model across Singapore and Vietnam, as the CEO has signalled (Edge 2026).
  • Vietnam national insurance access broadens FV's addressable market from 2026 (Vietnamese press).

Threats

  • Further FEMVN impairment: a 0.1-point rise in FEMVN's 14.4% discount rate cuts recoverable amount by S$4.8M; FEMVN goodwill still S$275.3M (FY2026 Note 11).
  • Refinancing concentration: S$175M of notes due May 2027 sit in current liabilities alongside S$26.8M of bank loans (FY2026 Note 15).
  • Payor action: Malaysian insurer contract terminations and price adjustments drove the 1H FY2025 loss (1H FY2025 media release).
  • Demographics: Singapore deliveries are declining (Phillip Securities, Sep 2026).
  • Currency: VND weakness cut Vietnam translated revenue growth to 2.9% despite volume growth (FY2026 Results).
  • Execution and partner risk on Johor Bay: no partner has been announced a year after launch; management says partner quality outranks timelines (Edge 2026).
  • Competition from larger, better-capitalised peers (IHH in all three markets; Vinmec and Tam Anh in Vietnam).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
17 May 2025FV Hospital announces US$45M new building (+6,700 sqm; total 37,500 sqm); FV received about 210,000 patients in the prior year Le Petit JournalCapacity for oncology, IVF, GI in Vietnam
FY2025 (by Jun 2025)Rejuvenated TMC officially opened with 24-hour Urgent Care and MRI Suite AR2025 summarySingapore revenue-intensity enabler
FY2025FV Hospital awarded fourth consecutive JCI accreditation AR2025 summaryQuality differentiator in Vietnam
25 Aug 2025Johor Bay launched: RM18bn GDV, 26 acres, JS-SEZ; shares closed at S$0.049 EdgeProp; ForbesMajor optionality on land bank
29 Aug 2025FY2025 results: revenue S$394.7M (+12.4%), net loss S$47.0M, S$75.1M FEMVN goodwill impairment, S$54.6M property impairment reversals FY2025 Press ReleaseFirst loss since FY2020
Aug 2025TMCLS FY2025 audited accounts: PATMI RM3.6M TMCLS AFS FY2025Malaysia trough
1 Sep 2025FY2025 results briefing SGX—
Sep 2025FSMOne credit update favours TMG 2027/2028/2029 notes; notes near-term maturities lightBond-investor support
Late 2025FV receives permission to expand grounds by 10,000 sqm Edge 2026Long-term Vietnam capacity
1 Jan 2026FV adopts national health insurance across services (press report) Bao Phap LuatVolume up, margin down
12 Jan 2026Tong Kooi Ong appointed Chairman (effective 1 Feb); board and committees reconstituted SGXGovernance; property expertise for Johor
31 Jan 2026Ng Ser Miang steps down after more than a decade as chairman SGX—
11 Feb 20261H FY2026: revenue S$213.1M (+7.0%); loss attributable S$10.2M (-20.6%); shares at S$0.062, up about 55% over 12 months 1H FY2026 Press Release; The EdgeRecovery signals
25 Feb 2026Phillip Securities: 1H EBITDA only 38% of full-year forecast; cuts FY26 EBITDA estimate 17% to S$84M; highlights Malaysia ABS jumps (inpatient +18%, outpatient +57%) POEMSExpectations reset
24 Apr 2026Aspire Surgery Centre incorporated (TMPL 40%) FY2026 announcementPartnership model extended to day surgery
1 Jun 2026Cassandra Loh named Acting CEO, Singapore, from 1 Jul SGXLeadership change in largest segment
1 Jul 2026Lee Suen Ming departs as Singapore CEO; Loh takes office Edge—
2 Jul 2026FEMVN enters US$1.0M uncommitted revolving working-capital facility FY2026 Note 17Local liquidity
FY2026THKD named among Asia's Top Private Hospitals and Clinics 2026 (Newsweek/Statista); MSQH 4-year accreditation; BFHI; ISO 15189 FY2026 BriefingMalaysia quality credentials
18 Aug 2026Shareholders' agreement with NVTS Specialists for Aspire Surgery Centre (S$1.12M for 40%) FY2026 Note 17—
26 Aug 2026FY2026 results: revenue S$420.1M (+6.4%); adjusted EBITDA S$82.5M (+9.9%); net loss S$27.8M; further S$15.2M FEMVN impairment (higher Vietnam discount rate 14.4%); no dividend; losses expected for next 12 months FY2026 Results AnnouncementNarrowing losses; Vietnam valuation risk persists
Aug 2026TMCLS FY2026 audited accounts: PATMI RM17.4M (FY2025: RM3.6M) TMCLS AFS FY2026Malaysia turnaround confirmed
28 Aug 2026FY2026 briefing: debt S$1.1bn; cash S$113.1M; net debt/adjusted EBITDA 12.1x; market cap S$1.4bn at 30 Jun FY2026 BriefingLeverage still high
2026 (interview)CEO says Johor Bay projected GDV S$5.5bn, hospital of 300-plus beds, in advanced talks with development partners; prioritises partner quality over timelines The Edge SingaporeMonetisation timing uncertain
11 Sep 2026Phillip Securities upgrades to BUY, target S$0.071; FY26 revenue/EBITDA 97%/98% of forecast; group inpatients -7.8% to 39,000 POEMSSell-side support
6 Oct 2026Shares trade at S$0.049 (market cap approx. S$1.30bn) MarketInOutShares back near Aug 2025 levels

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

12 charts
Income Statement: Revenue & Gross Profit: Revenue rose from SGD 333.7 Mn in FY2022 to SGD 420.1 Mn in FY2026.
Thomson Medical Group Limited — Income Statement: Revenue & Gross Profit
Series (SGD Mn)FY2022FY2023FY2024FY2025FY2026
Revenue333.7355.8351.2394.7420.1
Gross profit proxy (revenue less consumables; not reported by TMG)278.4296.4275.9295.3309.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.